MRNA vs BIIB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BIIB Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biogen Inc. Common Stock (BIIB) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus BIIB at 15.6x Forward P/E and 23.5% operating margin (+10.6% YoY). In options structure, MRNA sits in CONSOLIDATION (30th %ile IV; Dealer Gamma Walls on Pro) against BIIB sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MRNA Revenue | BIIB Revenue | MRNA Op. Margin | BIIB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $140M | $13.4B | -306.0% | 43.8% | BIIB |
| FY2019 | $60M | $14.4B | -906.8% | 49.0% | BIIB |
| FY2020 | $800M | $13.4B | -95.0% | 33.8% | BIIB |
| FY2021 | $18.5B | $11.0B | 72.0% | 25.9% | MRNA |
| FY2022 | $19.3B | $10.2B | 48.9% | 29.9% | MRNA |
| FY2023 | $6.85B | $9.84B | -61.9% | 11.8% | BIIB |
| FY2024 | $3.24B | $9.68B | -121.9% | 16.9% | BIIB |
| FY2025 | $1.94B | $9.89B | -158.1% | 13.1% | BIIB |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MRNA | BIIB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $93.6B | $37.0B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | 23.0x | 109.9x | Lower Multiple | MRNA |
| Forward P/E Ratio Valuation | 23.0x | 15.6x | Lower Multiple | BIIB |
| Revenue Growth (YoY) Growth | +29.2% | +10.6% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | -80.8% | 23.5% | Higher Margin | BIIB |
| Net Profit Margin Profitability | -110.5% | 3.4% | Higher Margin | BIIB |
| Return on Equity (ROE) Capital Efficiency | -34.5% | 1.9% | Higher ROE | BIIB |
| 52-Week Range Position Momentum | 75% ($22โ$281) | 92% ($160โ$261) | Stronger Trend | BIIB |
| Beta / 30D Volatility Risk Regime | 2.35ฮฒ ยท 101% Vol | 0.27ฮฒ ยท 36% Vol | Lower Realized Risk | BIIB |
| Unified Institutional Score Composite Signal | 46.8 / 100 (HOLD) | 50.2 / 100 (HOLD) | Higher Composite | BIIB |